Arcutis Biotherapeutics, Inc. (ARQT) has 13 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 9 sales totalling $1.0M. Most recent filing: Sept. 18, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 18, 2026 filed Sept. 16, 2026 | Matsuda Masaru See Remarks | −$91,853 | 3,674 | −3% | Yes | |
|
|
||||||
| Sept. 17, 2026 filed Sept. 15, 2026 | Welgus Howard G. Director | −$15,330 | 12,922 | −3% | Yes | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Matsuda Masaru See Remarks | −$249,986 | 9,989 | −8% | Yes | |
|
|
||||||
| Aug. 28, 2026 filed Aug. 27, 2026 | Curran Terrie Director | $669,241 | 114,600 | — | No | |
|
|
||||||
| Aug. 24, 2026 filed Aug. 20, 2026 | Curran Terrie Director | $19,862 | 3,216 | 0% | No | |
|
|
||||||
Showing the 5 most recent of 13 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free